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The misfolded prion protein causes and transmits disease in both humans and 
animals. As other infectious agents, prions display strain variation, which can generate 
different pathological outcomes in affected individuals. Unfortunately, there are no known 
therapies for these diseases, which at present are invariably fatal. In this work, the 
Protein Misfolding Cyclic Amplification technology (PMCA, an in vitro test that replicates 
minimum quantities of infectious prions) has been modified to screen for small molecules 
inhibiting prion protein misfolding in a strain-specific 
manner. In order to approach a high-throughput PMCA system, technical aspects in 
PMCA has been optimized for application of prions from laboratory rodents (i.e., mouse 
and Syrian hamsters) using a 96-well plate PMCA (96wp-PMCA) platform. Utilizing the 
96wp-PMCA technique, a small number of anti-prion and anti-amyloid molecules has 
been tested against these prion strains using different solvents and at varying 
concentrations. My results show that regardless of sequence homology, prion strains are 
differentially responsive to known protein misfolding inhibitors. Continual optimization of 
PMCA towards a high-throughput system may be used not only for screening therapeutic 
agents but also for diagnosis.  
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 1 
INTRODUCTION 
The cellular prion protein (PrPC) is naturally found in humans and animals (1). This 
protein can be found in a wide variety of tissues throughout the body. Specifically, it is 
found in higher concentrations in the brain, spinal cord, and lymphoid tissues (2, 3). From 
the cellular perspective, PrPC is located on the cell surface (4). Currently, the function of 
this protein in physiological processes is unclear (5). However, proposed functions 
associated with PrPC include protection of neurons from injury (6, 7), formation of 
synapses (8), or transport of copper into the cell (9–11). PrPC has also been identified 
as a possible receptor for amyloid-β (Aβ) oligomers which appear to be the main 
pathological effectors in Alzheimer’s disease (AD). However, based on studies showing 
that mice lacking the cellular prion protein display little or no abnormalities (12), it can be 
concluded that its functionality is not considered to be vital for cellular homeostasis or 
that its loss can be compensated for by other components. Under certain circumstances, 
PrPC can misfold into a disease-causing form referred to as PrPSc (13). The length of 
PrPSc and its amino acid composition are identical to PrPC. The difference between both 
entities lies in the secondary structure of the protein, with PrPSc consisting of more b-
pleated sheets in comparison to a-helices found in PrPC (1, 14).  Notably, the misfolded 
form of the prion protein is known to cause and transmit a group of disorders termed as 
Transmissible Spongiform Encephalopathies (TSEs, (15, 16)).  
 Prion diseases have been identified in several mammalian species, including 
humans (17). Human prion diseases can be classified into three categories: acquired, 
familial, and sporadic (18). Infection as a cause of human TSEs accounts for 
approximately one percent of cases (WHO). In these cases, infectious prions have been 
described as being introduced to humans through cannibalism (19), medical procedures 
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(20–22), and ingestion of beef products derived from cattle afflicted by bovine spongiform 
encephalopathy (23). Human exposure to these materials leads to diseases known as 
Kuru (24), iatrogenic Creutzfeldt-Jakob Disease (iCJD, (25)), and variant CJD (vCJD, 
(23, 26, 27)), respectively. Five to ten percent of cases can be classified as familial or 
hereditary (WHO). In these cases, patients with CJD, Gerstmann Straussler-Scheinker 
(GSS), and Fatal Familial Insomnia (FFI) can be found to have point mutations in the  
gene encoding the prion protein, resulting in accelerated misfolding and stabilization of 
the disease-causing PrP isoforms (28, 29). Similarly, as with other neurodegenerative 
diseases, the majority of human prion diseases are identified to be sporadic. Patients 
affected by sporadic cases are not infected or have a family history of the disease. This 
latter group includes sporadic CJD (sCJD, (30)), sporadic fatal insomnia ((31), and 
variable protease sensitive prionopathy (VPSPr, (32)). The events triggering the first 
misfolded process in sporadic TSEs are unknown, and likely occur in a stochastic 
manner (30).  Prion diseases are not selective towards humans and affect animals as 
well. In fact, the frequency of prion diseases in animals is significantly higher (33). There 
are a few types of animal prion diseases that can be considered prevalent. These include 
scrapie affecting sheep and goats (34), bovine spongiform encephalopathy affecting 
cows (35, 36), and chronic wasting disease (CWD) affecting cervid (37). All these TSEs 
have been found to exist in farm settings; however, only CWD has been identified in the 
wild as well (38–40). Due to the epidemic associated with CWD and its unclear zoonotic 
potential, this prion disease has recently gained research and public interest (41). 
Currently, efforts are being made by the scientific community and regulatory agencies to 
avoid unpleasant scenarios as the BSE epidemic that was experienced at the end of the 
last century (42). When an infected animal is identified in a farm setting, all animals that 
inhabit the same area are sacrificed in order to prevent the spreading of the disease. The 
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presence of an infectious animal in the wild can transport the disease across a large 
geographical distance.  
Both humans and animals affected by prion diseases develop unique pathological 
features as assessed by post mortem examination of brain and some peripheral tissues 
(43). These include spongiform degeneration (44), accumulation of disease-associated 
prion conformers (PrPSc) (45), loss of function and death of neurons (13), microglial 
activation (45), and astrocytes proliferation (46). Importantly, the clinical and pathological 
manifestation of TSEs within and across species is diverse. Compelling evidence has 
suggested that prion diseases originate from specific variants or “strains” of PrPSc (47). 
It is speculated that these different variants are a result of distinctive tertiary and 
quaternary conformations that PrPSc acquires (48). From a diagnosis standpoint, these 
strains may have specific biochemical properties that facilitate their identification and 
diagnosis (47). These biochemical characteristics, such as glycosylation pattern and 
structure of the protein, are distinctive of strains behaving differently. This can pose an 
obstacle in the pursuit of treatments against these diseases.  
 Currently, there are no cures or treatments against any type of prion disease in 
both humans and animals. Different laboratories have attempted to prevent or delay the 
onset of the disease. Most of these strategies have been assessed using in vitro assays 
or animal models of TSEs (49, 50). Unfortunately, the majority of therapeutic approaches 
have achieved modest effect through the extension of the incubation period for the 
disease (51, 52). Therapeutic strategies explored against TSEs can be organized 
broadly into three categories: (i) treatment-based approaches (gene therapy, 
immunizations, manipulations at the immune system level, and cell-based therapies), (ii) 
small molecules (altering either prion replication or cell signaling cascades), and (iii) prion 
competition treatment. Some of these experimental approaches have been seen to delay 
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onset of the disease (53), act as a prophylaxis through protection from the disease (54–
56), or suppress prion replication (57). Unfortunately, the majority of these treatments 
have only been tested against a select number of strains. Predominantly, these strains 
belong to laboratory adapted rodent prion strains and not strains present naturally in 
humans or animals. Due to the proposition that these strains are a result of different 
conformations, an avenue that has shown promising results for one specific prion strain 
may not be proficient against a second one (58).  
 To study prion diseases in the laboratory setting, animal models such as mice and 
Syrian hamsters have been utilized (47). Unfortunately, there is a high monetary cost 
associated with these models due to their long incubation periods for disease 
manifestation (being as long as 450 days). Because of the need to test a large array of 
compounds for activity against prion replication, this experimental format is unviable. The 
Protein Misfolding Cyclic Amplification (PMCA) technique has been shown to replicate 
conformational properties of infectious prions while maintaining their biologically relevant 
features (59). This technique allows for the production of a large amount of the infectious 
prion protein (PrPSc) at the expense of PrPC through multiple cycles consisting of 
incubation and sonication (Figure 1). The incubation periods allow for the recruitment 
and conversion of PrPC to PrPSc which adds to the PrPSc aggregates. In order to expose 
more free ends of the aggregates to aid in the conversion process, sonication causes 
the aggregate to be broken. Due to its sensitivity and simplicity, PMCA can be used for 
several purposes, including: screening of biological samples (60), modeling of prion 
strains and the species barrier phenomena (61), effectiveness of different strategies to 
remove prions from biological samples (62), diagnosis of human and animal prion 
diseases (63–65)), and many others.  
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Figure 1. Graphical representation for protein misfolding cyclic amplification. The 
in vitro technique is based on the nucleation polymerization principle of protein 
aggregation. The PrPSc aggregates recruits and converts PrPC during the incubation 
period, and sonication allows for more free ends available to aid in the conversion 
process. Multiple cycles of incubation and sonication occur during the PMCA process.  
Incubation 
Incubation 
Sonication 
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For this master’s thesis, I focused on establishing a protocol that increases the 
actual throughput of the PMCA technology with the goal to screen a small selection of 
known anti-prion and anti-amyloid molecules. Six rodent prion strains associated with 
mice and hamsters were chosen for this project. The mouse prion strains included the 
Rocky Mountain Laboratory Strain (RML, (66, 67)), 301C (68), and ME7 (69–71) 
(originated from scrapie, bovine spongiform encephalopathy, and scrapie, respectively). 
Hamster prions comprised HY (72), SSLOW (73), and 263K (74) (with sources of scrapie, 
in vitro misfolded recombinant PrP, and transmissible mink encephalopathy, 
respectively). I chose these strains because they have been readily used to model and 
study prion diseases in a laboratory setting and their distinct biochemical (and 
presumably structural) features. My working hypothesis is that by modification of PMCA 
for high-throughput screening of small molecules, I will find strain specific anti-prion 
agents.  
 In order to utilize the PMCA technique to screen small molecules, I modified 
PMCA for a 96-well plate (96wp) format for different prion strains. Modifications to 
different parameters, including, but not limited to, composition of the PMCA conversion 
buffer, alterations on incubation and sonication periods and sonication power, and signal 
analysis performed via dot blotting, which is in considerably faster when compared to 
currently used western blots, were made in order to standardize 96wp-PMCA. I aimed to 
decrease the reagents needed and the time required for PMCA in order to advance the 
technique in a high-throughput format.  
 After the standardization of 96wp-PMCA, I used this technique to screen a small 
selection of molecules, which possess proven anti-prion capabilities in different systems 
(mostly cell-based). Anti-prion molecules and anti-amyloid molecules were evaluated 
against six rodent prion strains. The anti-prion molecules have been tested against a 
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selected number of prion strains belonging to human and animals (49, 75) while the anti-
amyloid molecules are compounds which have been shown to inhibit the replication of 
non-prion amyloids (76).  
From these aims, with the standardization of 96wp-PMCA and its application for 
the screening of small molecules, I completed the main goal of identifying small 
molecules able to inhibit the in vitro prion misfolding process against different strains. 
The long-term goal will be for these identified molecules to be tested in animal models, 
and prospectively utilized in clinical trials. Additionally, this technology may be optimized 
to further increase its throughput and identify novel strain-specific inhibitors. In addition, 
the standardized principles of the 96wp-PMCA platform could be applied towards other 
diseases involving the accumulation of misfolded proteins, such as, Alzheimer’s and 
Parkinson’s disease. The PMCA technique can be further modified and optimized in 
order to attain a high-throughput screening system.  
 
MATERIALS AND METHODS 
Preparation of Brain Tissue 
Wild-Type (WT) mouse or hamster brains were collected from animals euthanized by 
CO2 inhalation based on University and Federal guidelines. After euthanasia, animals 
were subjected to cardiac perfusion. Perfusion buffer was created by adding 5 mM EDTA 
(Fisher Scientific Company PR-V4231) to 1X PBS (Fisher Scientific Company 
SH30256LS). Each animal was manually perfused with 30 mL of perfusion buffer. After 
perfusion, brains were removed, rinsed in perfusion buffer, frozen in liquid nitrogen and 
stored at -80°C. Prion-Infected mice or hamsters were euthanized by CO2 inhalation once 
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reaching advanced clinical stages of prion disease as previously described (77, 78). 
Collected brains were stored at -80°C until used.  
 
Preparation of PMCA Substrate  
Conversion Buffer (CB) was made consisting of: 150 mM NaCl (Sigma Aldrich S3014), 
1% volume/volume (v/v) Triton X-100 (Sigma Aldrich T9284) and 1X PBS, pH 7.0-7.3. 
Before use, 50 mL of CB was supplemented with a complete protease inhibitor (PI) 
cocktail tablet containing EDTA (Thermo Fisher Scientific PIA32965). Perfused wild-type 
brains were weighed and combined with conversion buffer (CB) containing PI to generate 
a 10% weight/volume (w/v) homogenate that was prepared in ice-cooled Potter-Elvehjem 
tissue grinders. Homogenates were centrifuged at 800 x g at 4°C for 45 s. Pellets were 
disposed of while supernatants were well-mixed by vortexing and then placed on ice. 
Supernatants were aliquoted, frozen in liquid nitrogen, and stored at -80°C. All the 
procedures mentioned above were performed using prion-free facilities and equipment. 
These aliquots, which are the final PMCA substrate, are referred to as normal brain 
homogenate (NBH).  
 
Preparation of Inoculum  
The protocol is similar to the substrate preparation aside from the following:  
homogenization buffer was prepared by mixing one complete PI tablet with EDTA in 1X 
PBS. The prion-infected brain was homogenized in 10% w/v, as described above and 
centrifuged. Supernatants were mixed, aliquoted and stored at -80°C until use.  
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96-well plate PMCA (96wp-PMCA) 
PMCA protocol was extensively modified from previously described procedures (79). 
Two teflon beads (PTFE Grade Balls 3/32) (Hoover Precision Products) were added to 
each well of 96-well plates (Thomas Scientific C18096). Prions were added to each well 
in amounts varying from 1 x 10-2 to 1 x 10-5 % w/v brain homogenate equivalent by dilution 
in NBH. Each reaction was performed in a total volume of 50 μL. Samples were covered 
with twelve strip lids (Thomas Scientific C18096-C) and plates were placed in the horn 
of a Qsonica Q700 automatic sonicator system. The overall length of each passage was 
between 24 and 48 hrs.  Each PMCA cycle consisted of continuous cycles of 29 min and 
40 s of incubation followed by 20 s of sonication. During the PMCA procedure, the 
sonicator horn is inside an incubator set at 37°C. PMCA reactions were additionally 
supplemented with different concentrations of ethanol or dimethyl sulfoxide, or small 
molecules dissolved in these solvents (small molecule concentrations varying from 100 
µM to 0.1 µM). Negative controls consisted of unseeded PMCA reactions.  
 
Analysis of 96wp-PMCA Products 
Each well from 96wp-PMCA was treated with proteinase K (PK) (Sigma Aldrich P2308) 
at a 100 μg/mL final concentration. After PK was added to the wells, the plate was placed 
in an Eppendorf Thermomixer for 1 hr at 37°C set to perform 450 rpm. To stop the PK 
reaction, 5 mM of phenylmethane sulfonyl fluoride (PMSF) (Fischer Scientific Company 
AC215740050) was added to each well and incubated at 70°C for 10 min. Samples were 
then assessed for the presence of PK-resistant PrP either by western blot or dot blot. For 
dot blots, Whatman Gel Block Paper (GE Healthcare Life Science 10427812) was placed 
onto a Bio-Dot Apparatus (Bio-rad 1706455) followed by a nitrocellulose membrane 
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(Fischer Scientific Company 45-004-003). From each well, 5 μL of content was placed 
directly onto the nitrocellulose membrane. Membranes were dried using a blow dryer and 
then transferred into an incubation chamber containing 10 mL of 3M guanidinium 
thiocyanate (Fischer Scientific 50-491-761) for 10 min. Later, membranes were rinsed 
three times with 50 mL of washing buffer (0.05% Tween in 1X PBS) and then transferred 
to a 10% blocking solution consisting of 5% w/v dry nonfat milk (Fischer Scientific 
Company NC9952266) dissolved in washing buffer. Membrane blocking lasted 1 hr and 
was performed by placing the membrane on a rocking platform at room temperature. The 
membrane was later incubated with monoclonal 6D11 anti-prion antibody (Santa Cruz 
Biotechnology sc-58581) at a 1:10,000 dilution in 5% w/v blocking buffer for 1 hr on a 
rocking platform at room temperature followed by 3 washes (10 min, 5 min, and 5 min) 
with washing buffer. Membranes were then incubated with a horseradish peroxidase-
linked polyclonal antibody mouse IgG (Sigma Aldrich A5906) at a dilution of 1:3,000 in 
5% w/v blocking buffer for 1 hr on a rocking platform at room temperature. The membrane 
was again washed for 10 min, 5 min, and 5 min with washing buffer and developed using 
an ECL system following manufacturer’s recommendations (Fisher Scientific 45-002-
401). For western blots, a similar procedure was performed, with the difference that PK 
digested samples were previously fractionated in SDS-PAGE and transferred to 
nitrocellulose membranes as described (79). 
 
RESULTS 
Optimization of Parameters for Dot Blot Analysis 
Conventional PMCA procedure classically involves detection of PrPSc signals by 
western blots (79). The utilization of conventional PMCA could be an option for the 
screening of small molecules. However, I chose to optimize conventional PMCA for a 96-
 11 
well plate format because the amount of time involved could be drastically reduced by 
the use of an alternative detection method, increasing the throughput and number of 
samples to be analyzed. I chose the dot blot method due to its proven efficiency for prion 
detection (80), the reduced time of this technique compared to western blots, and the 
reduced volume of sample needed to obtain clear readouts. Aside from alterations to the 
PMCA process, analyzing the samples with dot blots should reduce analysis times from 
two days to one day compared to currently used western blots.  
In order to achieve a high-throughput PMCA screening system in the future 
through further modifications, the levels of samples for the assay and detection should 
be reduced. In that sense, the minimum volume of PMCA products to be used in dot blots 
must be determined. Importantly, positive readings obtained at the selected volume 
should be homogeneous across the plate. For that purpose, I used a 10% w/v brain 
homogenate from a mouse infected with the RML prion strain. Three different volumes 
were utilized, including 3 μL, 5 μL, and 7 μL (Figure 2). These volumes are substantially 
lower than the 20-30 µL regularly utilized in western blot detection (79). Ninety-six 
aliquots of the same brain preparation were placed directly on the nitrocellulose 
membrane. Because the samples used consisted of concentrated infectious material, I 
expected that positive signals should be detected throughout the entire membrane. All 
dot blots in this project were evaluated in an all-or-none fashion. These membranes did 
not contain negative control wells in order to assess for uniform signal across the plate. 
With only 3 µL used, signal was not uniformly detected for all the samples (Figure 2A). 
On the contrary, both the volumes of 5 µL and 7 µL generated uniform results across the 
plates. These experiments were performed in duplicates with reproducible outcomes. I 
determined the optimal minimum volume of the samples required for analysis to be 5 µL 
due to the desire to use the lowest sample volume possible.  
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Figure 2. Effects of sample volume utilized in dot blot analysis. Three different 
volumes (3μL (A), 5μL (B), and 7μL (C)) of 10% weight/volume (w/v) brain homogenate 
prepared from the brain of a terminally ill mouse infected with the Rocky Mountain 
Laboratory (RML) prion strain were directly placed on nitrocellulose membranes as 
described in Methods. These samples were not PK-treated.  
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In addition to the reduction in sample volume, processing time was decreased as 
well. A major time constraint in the classical PMCA setup is seen in the primary antibody 
incubation time. Based on current western blot protocols used to analyze PMCA 
products, the standardized time required for primary antibody incubation is sixteen hours 
(81, 82). Considering that several primary antibodies work at one hour of incubation (79, 
83), I decided to try the same on my developing dot blot protocol. Similar to the 
experiments shown in Figure 2, I used 10% w/v brain homogenate from a terminally ill 
mouse brain infected with the RML prion strain as sample. Ninety-six aliquots of 5 μL 
each of this material were loaded directly on the nitrocellulose membrane. For 
comparison, two incubation times were tested (1 and 16 hrs, Figure 3). I concluded that 
one hour of primary antibody incubation was sufficient for the dot blot to yield positive 
signals in all wells, similar to what was observed by incubating the membrane with the 
conventional 16 hours. The reduction of the primary antibody incubation duration 
contributed to the decrease of time required for the analysis of the samples.  
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Figure 3. Reduction of primary antibody incubation times does not affect dot blot 
readout. 5 µL aliquots from a 10% weight/volume (w/v) brain homogenate prepared 
using a brain from terminally ill mice infected with the Rocky Mountain Laboratory (RML) 
prion strain were directly placed on nitrocellulose membranes. These samples were not 
PK-treated. Primary antibody (6D11) incubation was tested for two different durations, 
lasting either 1 hr (A) or 16 hrs (B).  
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Optimization of the 96wp-PMCA 
The next step was to modify PMCA with the intention of optimizing it towards a 
high-throughput format. For that purpose, I modified this technique for its use in 96-well 
plates instead of currently used individual tubes.  While using plates, I tested 
modifications of PMCA components such as passage duration, sample volume in each 
well, and specifications of the sonicator to accommodate for the number of samples. 
Current settings used in conventional PMCA may work differently in the 96 well plate 
format and should be tested. Based on previous research performed, the PMCA process 
may require supplementation in order to work efficiently (79). Ethylenediaminetetraacetic 
acid (EDTA) is a chelating agent that binds to divalent cations, particularly copper (II) 
ions in solution. Divalent cations have been shown to inhibit prion replication in PMCA 
(84, 85) Similar results have been observed for prions bound to metallic surfaces where 
the release of cations into the PMCA reaction are likely the cause for reduced or no 
replication ((86) and unpublished data). Due to the interaction that occurs between the 
prion protein and divalent ions, the usage of EDTA can prevent unwanted interactions 
and allow for PMCA to be more efficient. I tested two concentrations of EDTA in 96wp-
PMCA, including 0 mM (using protease inhibitor that was EDTA-free) and 1 mM (using 
a complete protease inhibitor) supplemented into normal brain homogenate containing a 
1x10-4 % w/v dilution of an RML-infected brain homogenate. Samples from both tested 
conditions were PK treated prior to dot blot analysis. My results showed no signal for 
samples in the EDTA-free context while in the presence of 1 mM EDTA uniform positive 
signals were seen (Figure 4A). I concluded that in the absence of EDTA, the PMCA 
process is hindered and 1 mM of EDTA is required for PMCA to work efficiently.  
To further reduce the time required for HT-PMCA, I needed to reduce the number 
of incubation/sonication cycles. In traditional PMCA, multiple passages (rounds) each 
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involving several incubation/sonication cycles are required (79). Each PMCA round 
classically comprises durations between 24 hrs and 72 hrs. Extended times per PMCA 
round are required to obtain a uniform amplification throughout all samples placed in the 
sonication horn (79). For my assay, I decided to test 24 and 48 hrs in a single PMCA 
round. I observed comparable results for both times tested and selected the one of 24 
hrs cycle time for further assays (Figure 4B). 
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Figure 4. Effects of EDTA supplementation and PMCA passage duration in 96wp-
PMCA. Modifications to optimize PMCA for a 96 well-plate format included changes at 
the conversion buffer and incubation/sonication levels. (i) Normal wild-type brain 
homogenate (PMCA substrate) was subjected to 0 mM (A) or 1mM (B) of EDTA 
supplementation in conversion buffer used to homogenized samples. Normal brain 
homogenate was utilized to make a 1 x 10-4 % w/v RML brain homogenate dilution and 
subjected to one PMCA passage of 24 hrs.  (ii) Similar samples as described in (A) (EDTA 
supplemented) were subjected to PMCA passages of 24 hrs (C) or 48 hrs (D).  
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As previously stated, the amount of PrPSc seeds in the PMCA reaction was 
another component which required optimization in order to approach this technique for a 
high-throughput format. Therefore, it was essential to determine the lowest dilution that 
can be utilized without jeopardizing uniform amplification of prions across all positions in 
the 96-well plate. The main purpose of manipulating PMCA for a 96-well plate was to 
provide a new avenue to use the technique for the screening of small molecules; 
therefore, the lower dilution would be beneficial to maximize the probability of identifying 
prospective molecules while also isolating efficient drugs. I tested, in my developing 
96wp-PMCA assay, four concentrations of RML prions in regards of the dilution of an 
infected brain homogenate: 1 x 10-2, 1 x 10-3, 1 x 10-4 and 1 x 10-5 % w/v (Figure 5). 
PMCA products derived from each of the four dilutions were PK-treated and analyzed. 
Uniform amplification can be seen at all four concentrations. When the dilution of 10-5 
was tested against the other prion strains of interest, I was unable to detect uniform 
amplification of the samples (not shown). After testing the dilution of 1 x 10-4 % w/v for 
other strains, I was able to conclude that the appropriate dilution across multiple strains 
would be 1 x 10-4% w/v.  
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Figure 5. Effects of varying PrPSc dilutions in 96wp-PMCA performance. Varying 
dilutions of RML brain homogenates (1 x 10-2 (A), 1 x 10-3 (B), 1 x 10-4 (C), and 1 x 10-5 
(D) % w/v) were tested for detection using 96wp-PMCA for 24 hrs. All PMCA products 
were PK treated before analysis through dot blots.  
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In summary, my modifications to use PMCA in a 96 well plate format included the 
supplementation of 1 mM EDTA into the normal brain homogenate (Figure 4A) and 
supplementation of seeds at a 1 x 10-4 % w/v dilution of infected brain homogenate 
(Figure 5B). These conditions fulfilled my requirements of uniform amplification across 
the 96 well plate for multiple rodent prion strains. Aside from alterations to the actual 
PMCA process, I made other changes including the utilization of two teflon beads each 
in comparison to three teflon beads, and reduction of the overall volume in well from 90 
µL to 50 µL. Comprehensively, these changes allow for PMCA to be modified for a 
scheme that is more optimal for the screening of small molecules targeting the prion 
misfolding process. A summary of the changes implemented for the 96wp-PMCA 
compared to conventional PMCA are listed in Table 1.  
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Standardization of Experimental Prion Strains  
Based on the parameters established above, I tested the in vitro amplification 
performance of six rodent prion strains. Specifically, I used three mouse-derived prion 
strains (RML (66, 67), 301C (68), and ME7 (69–71)) and three hamster-derived prion 
strains (HY (72), SSLOW (73), 263K (74)). All these strains originated from different 
sources, including sheep (RML, ME7), goat (263K), mink (HY), bovine (301C) prions, or 
synthetically derived (SSLOW). The Rocky Mountain Laboratory (RML) strain was 
chosen because several compounds halting its replication have been identified (49). The 
other strains were chosen based on their suspected different conformations. As 
mentioned, my working hypothesis is anti-prion molecules will have different responses 
depending on the prion strain that they are tested against.  Each of these six strains were 
subjected to 24 hours of 96wp-PMCA at a 1 x 10-4 % w/v brain dilution of seeds. 
Additionally, 4-6 negative control (non-seeded) samples were included to assess for 
possible cross-contamination during PMCA and handling of samples. After PMCA, all 
samples were PK-treated to remove non-misfolded PrP and 5 µL from each well were 
dispensed onto nitrocellulose membranes for analysis. I observed uniform amplification 
for the mouse and hamster prion strains (Figure 6 and Figure 7, respectively). Negative 
control samples resulted in no signal, as expected. I further confirmed the presence of 
bona-fide PrPSc by western blot (not shown).  
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Figure 6. Standardized 96wp-PMCA for three mouse prion strains. From top to 
bottom, 10-4 dilutions of RML (A), 301C (B), and ME7 (C) prions, respectively, were 
subjected to 24 hrs of 96wp-PMCA. Each plate contained 4-6 negative control wells as 
depicted in white on the corresponding diagram (left panels). In these control samples, 
no PrPSc added as described in Methods.  
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Figure 7. Standardized 96wp-PMCA for three hamster prion strains. From top to 
bottom, 1 x 10-4 % w/v dilutions of HY (A), SSLOW (B), and 263K (C) prions, respectively, 
were subjected to 24 hrs of 96wp-PMCA. Each plate contained 4-6 negative control wells 
as depicted in white on the corresponding diagram. In these control samples, no PrPSc 
added as described in Methods.  
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Due to the intention of testing a wide range of molecules, and in order to account 
for molecule solubility in varying solvents, I tested the effect of dimethyl sulfoxide (DMSO) 
and Ethanol (EtOH) on 96wp-PMCA performance. This experiment was necessary in 
order to determine that the effects seen in the presence of the tested compounds were 
not due to the solvents in which they were dissolved. Plates were set up with two strains 
from each animal species, specifically RML and 301C for mice and HY and 263K for 
hamsters. For all prion strains, a 1:2 dilution gradient was set up for each of the solvents 
(starting from 8% v/v of solvent in each case). As seen in Figure 8, amplification of the 
mouse prion strains displayed inhibition only at 8% EtOH but no inhibition at any of the 
DMSO concentrations tested (Figure 8A). For hamster prions, inhibition of 263K 
replication was seen at 8% ethanol, while HY displayed inhibition with EtOH at 8% and 
4% (Figure 8B). Overall, these data suggest that PMCA is impacted at these specific 
concentrations; therefore, molecules should be dissolved in concentrations where 
inhibition is not seen. I therefore dissolved all compounds in 1% v/v of solvent and tested 
their effects on in vitro prion replication using my 96wp-PMCA format.      
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Figure 8. Effects of drug solvents in 96wp-PMCA. Prospective solvents, DMSO and 
ethanol, were tested at eight different concentrations (ranging from 8% to 0.0625%) 
against two mouse strains (A) and two hamster strains (B).  
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Evaluation of compounds in 96wp-PMCA 
Next, the optimized 96wp-PMCA set up was used to test the effect of a small 
selection of known anti-prion (Figure 9) and anti-amyloid (Figure 12) molecules against 
the six prion strains previously shown to replicate in this format. The majority of the anti-
prion molecules were chosen due to their previously reported effectiveness against RML 
prions in a cell-based in vitro assay (49). The six anti-amyloid molecules chosen in this 
thesis work have been previously tested for their activity against misfolded proteins 
involved in Alzheimer’s and Parkinson’s Disease (76, 87, 88). Importantly, the anti-prion 
activity of the latter set of compounds has not been studied. All compounds were 
dissolved, based on their solubility, in either 1% v/v DMSO or 1% v/v ethanol. In the 
appropriate solvents, four concentrations (100 µM, 10 µM, 1 µM, and 0.1 µM) of each 
molecule were used to supplement 96wp-PMCA reactions. The total volume of each well 
after the addition of the molecules was 50 µL as described in my previous optimization 
of the assay. Each 96-well plate also contained proper controls, including negative 
control samples and seeded wells supplemented with solvents only. To assess for 
reproducibility, each condition was tested in triplicates (each replicate in a different plate).  
The mouse strains (RML, 301C, and ME7) were tested against ten anti-prion 
molecules; astemizole, Congo red, curcumin, quinacrine dihydrochloride, imatinib, 
resveratrol, tannic acid, tetracycline hydrochloride, thioflavin T, and tetrandrine (Figure 
10). Each of these molecules have been tested against a select number of strains for its 
inhibitory effects in varying models. From the ten molecules tested, inhibition in prion 
replication was observed only with three of the them (Congo red, tannic acid, and 
thioflavin T). Although the same three molecules were effective against all three mouse 
strains, a difference in lowest concentration of inhibition was seen for two of them: Congo 
red and thioflavin T. For 301C prions (Figure 10B), both of these molecules displayed 
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inhibition at 10 µM. This was different from the 100 µM effective concentration observed 
for RML prions (Figure 10A). In comparison to the other two mouse prion strains, ME7 
(Figure 10C) was only inhibited by tannic acid. When these anti-prion molecules were 
tested against the hamster prion strains (HY, SSLOW, and 263K, Figure 11), Congo red, 
tannic acid, and thioflavin T caused inhibition of these strains as well. In addition to those 
three molecules, curcumin was shown to inhibit HY at 100 µM when dissolved in EtOH 
(Figure 11A). This molecule also inhibited 263K misfolding at 100 µM in both solvents 
(Figure 11C). Table 2 and Table 3 summarize the lowest concentration of compounds 
capable of inhibiting in vitro replication on each prion strain. These results support my 
hypothesis that the effectiveness of molecules with anti-prion activity may vary 
depending on the prion strain that is tested.   
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Figure 9. Selection of anti-prion molecules. Ten known anti-prion compounds were  
chosen to be evaluated for inhibitory effects in 96wp-PMCA against rodent prion strains. 
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Figure 10. Evaluation of known anti-prion small molecules in 96wp-PMCA (mouse 
prion strains). Ten known anti-prion compounds were tested at four different 
concentrations in either DMSO or EtOH for their activity against RML (A), 301C (B), and 
ME7 (C) in vitro replication. Each molecule was tested in concentrations ranging from 
100 µM to 0.1 µM. Controls for solvents and positive samples and negative samples 
without compounds were included to monitor the assay. Dot blots were modified for 
labeling. Figure is representative from three independent assays. 
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Figure 11. Evaluation of known anti-prion small molecules in 96wp-PMCA (hamster 
prion strains). Ten known anti-prion compounds were tested at four different 
concentrations in either DMSO or EtOH for their activity against HY (A), SSLOW (B), and 
263K (C) in vitro replication. Each molecule was tested in concentrations ranging from 
100 µM to 0.1 µM. Controls for solvents and positive samples and negative samples 
without compounds were included to monitor the assay. Dot blots were modified for 
labeling. Figure is representative from three independent assays. 
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The replication of mouse prion strains (RML, 301C, and ME7) was also tested in 
the presence of six molecules; azure A, azure B, azure C, quinacrine mustard 
dihydrochloride, rhodanine, and thionin acetate salt, proven to be active against other 
amyloidogenic proteins (76) (Figure 13). Assays were performed in a similar fashion as 
depicted in Figure 10. From the six tested molecules, four of them inhibited replication 
for all mouse prion variants (azure A, azure B, azure C, and thionin acetate). Specifically, 
azure B and azure C were effective at 1 µM against RML (Figure 13A) and ME7 (Figure 
13C). The four molecules that displayed inhibition did so at different concentrations that 
were dependent on the prion strains they were evaluated against. In a similar trend to 
the anti-prion molecules, I am able to see strain specific patterns of inhibition for the anti-
amyloid molecules as well. In addition to the four molecules that were effective against 
mouse strains, quinacrine mustard showed clear anti-prion activity against all the 
hamster prions tested in this project (Figure 14). Although inhibition was detected across 
the three hamster prion strains, it is important to acknowledge that effect occurred only 
at the highest concentration tested (100 µM). The molecule displaying the lowest anti-
prion activity against hamster prions was azure C (effective at 1 µM against HY prions) 
(Figure 14A). Table 3 summarizes the lowest concentration displaying anti-prion activity 
each hamster prion strain for both anti-prion and anti-amyloid molecules. When 
evaluating the results across both species and both groups of molecules, it becomes 
evident that there may be a prion strain selective pattern of activity. Depending on the 
strain that the molecule was tested against and the solvent, a selection of the compounds 
was discovered to have distinct inhibition concentrations.  
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Figure 12. Selection of anti-amyloid molecules. Six known anti-prion compounds 
were chosen to be evaluated for inhibitory effects in 96wp-PMCA against rodent prion 
strains.  
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Figure 13. Evaluation of known anti-amyloid small molecules in 96wp-PMCA 
(mouse prion strains). Six known anti-amyloid compounds were tested at four different 
concentrations in DMSO and EtOH for their activity against RML (A), 301C (B), and ME7 
(C) in vitro replication. Controls for solvents and positive samples and negative samples 
without compounds were placed on the plate to control the performance of the assay. 
Dot blots were modified for labeling. Figure is representative from three independent 
assays. 
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Figure 14. Evaluation of known anti-amyloid compounds in 96wp-PMCA (hamster 
prion strains). Six known anti-amyloid compounds were tested at four different 
concentrations in DMSO and EtOH for their activity against HY (A), SSLOW (B), and 
263K (C) in vitro replication. Controls for solvents and positive samples and negative 
samples without compounds were placed on the plates to control the performance of the 
assay. Dot blots were modified for labeling. Figure is representative from three 
independent assays. 
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DISCUSSION AND CONCLUSION 
 The Protein Misfolding Cyclic Amplification (PMCA) technology was an 
appropriate option to be used for this project due to (i) its ability to replicate the 
conformational properties of infectious prions while maintaining all their biologically 
relevant features (including strain specific properties, (61)), (ii) each assay can be 
completed in a relatively short time, (iii) it represents a low cost technology, suitable for 
screening large number of samples. Based on the other applications of PMCA, I believed 
that the technique could be optimized for high-throughput identification and evaluation of 
small molecules with presumed anti-prion activity.  
 High-throughput screening (HTS) allows for a large number of samples to be 
tested against a specific target. This is performed by the utilization of automatization and 
reduction of assay components allowing for the process to occur effectively, efficiently, 
reproducibly and at minimum cost (89).  A selected number of modifications would need 
to occur in order to achieve the development of a high-throughput PMCA (HT-PMCA) 
platform. In my project, I did not achieve the establishment of a HT-PMCA platform since, 
at its current status, my optimized platform allows the screening of compounds at a 
medium throughput range. However, I believe that the establishment of a 96-well plate 
PMCA (96wp-PMCA) assay represents an important step forward in that direction. 
Modifications of PMCA that I aimed to achieve with the 96wp-PMCA included the 
decrease amount of time and volume that is required to complete the assay. In 
comparison to conventional PMCA, I also decreased the number of teflon beads 
required, lowered the volume of material to be utilized, substantially increased the 
number of samples to be tested per PMCA assay, and decreased the length of the overall 
process (Figures 2-5 and Table 1). All these manipulations were effective in reducing the 
overall cost associated with this technique.  
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The first step on this optimization path was to determine the minimum volume of 
samples that would be required to allow for proper analysis. Importantly, the selection of 
such volume should fulfill the criteria of being reproducible across the whole 96 well plate 
in independent assays.  In order to establish this volume, it was crucial to determine the 
volume that would be required to evaluate the samples with dot blot. I directly placed 
three different volumes of 10% w/v brain homogenate prepared from terminally ill mice 
infected with the RML prion strain onto a nitrocellulose membrane (Figure 2). From this 
experiment, I determined the volume of the sample required for dot blot analysis to be 5 
μL. In parallel, I also determined that the PMCA reaction can be performed in a volume 
as low as 50 μL. The latter assay volume was determined to be the minimum possible 
since it allows for 2 teflon beads to be completely submerged (Teflon beads are known 
enhancers of PMCA while buffering reproducibility across different assays (90–92)). The 
beads are able to assist in the breaking of the PrPSc and provide additional surface area 
for the conversion of PrPC to PrPSc to occur. A significant amount of time in the 
conventional PMCA assay was attributed to the incubation period of the primary 
antibody. Therefore, it was my goal to decrease the time dedicated to this critical step 
(Figure 3). Since I saw comparable results when comparing the 16 hrs and 1 hr 
incubation time, I was able to determine that 1 hour was sufficient for my purposes.  
 I can see that PMCA is unable to occur effectively when EDTA is not 
supplemented into the brain homogenate (Figure 4). Although the mechanism is unclear, 
the presence of cations has been hypothesized to prevent or delay the replication 
process (84, 85). Since PMCA is a process that focuses on protein-protein interactions, 
I hypothesize that the cations in solution may be interacting with either PrPSc or PrPC 
preventing the desired interaction to occur. Consequently, the usage of 1 mM EDTA is 
shown to render these cations unable to hinder the PMCA process. The purpose of the 
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results shown in Figure 5 focused on finding the lowest dilutions where amplification can 
be seen uniformly across the plate. I was able to see uniform amplification for the RML 
strain at 1 x 10-5 % w/v; however, for other strains (not shown) uniform amplification was 
only seen up to a dilution of 1 x 10-4 % w/v. In that sense this dilution of infectious prions 
was used to supplement the 96wp-PMCA reactions in future assays. 
With the transition from using PCR strip tubes to a 96-well plate, it was necessary 
to optimize 96wp-PMCA for more than one prion strain. Optimizing the platform for a 
selection of strains allows for the accommodation of different species and distinct 
characteristics associated with each strain. Importantly, and due to the high sensitivity of 
the PMCA assay (93), I had to verify the validity of the technique through the presence 
of negative control samples (to assess for possible inter-well cross-contaminations). The 
first step included testing the performance of six different rodent prion strains in my 
assay, considering all above-mentioned optimized conditions and requirements. In 
summary, I successfully achieved optimal 96wp-PMCA assays for mouse (Figure 6) and 
Syrian hamster (Figure 7) prions. Through the random placement of negative controls 
for each of the prion strains tested, I am able to conclude that uniform amplification of 
the samples occurred regardless of their placement location on the plate. Biochemically, 
prion strains can be distinguished by western blot due to their differential PK resistant 
core (different lengths) or their glycosylation profiles (47). One of the limitations of using 
dot blots for analysis of PMCA-derived samples from multiple strains is the incapability 
to distinguish them.   To account for this restriction, each assay only tested a single prion 
strain and the signal was assessed in an all-or-none fashion.  However, to verify that the 
PMCA did not alter the strain properties of each selected agent, I ran selected samples 
by western blots (not shown).  
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The next step in my proposed project was to validate the 96wp-PMCA assay for 
the screening of small molecules harboring anti-prion activity. As regular practice, 
compounds from libraries are dissolved in different solvents, DMSO and EtOH being the 
most widely used. These solvents were evaluated independently in the 96wp-PMCA to 
determine if they would influence the prion replication process. Inhibition was seen at 8% 
v/v EtOH in both mouse and hamster prion strains. Additionally, I also observed inhibition 
at 4% EtOH with the HY prions (Syrian hamster strain). On the other hand, I did not see 
any inhibition with DMSO at any of the concentrations tested for the mouse or hamster 
strains.  Despite the ability for these solvents to inhibit the in vitro conversion of some of 
the tested prion strains, I was not majorly concerned since I dissolved all molecules at 
1% v/v of each or both solvents. Since the solvent concentration chosen does not show 
hinderance of in vitro conversion, any inhibition observed in the presence of small 
molecules can be attributed to the molecule itself.  
The majority of the anti-prion molecules tested in this study (Figures 10 & 11) were 
selected on their ability to inhibit RML in neuroblastoma cell lines at nanomolar 
concentrations (49). Thioflavin T was chosen as a molecule to test due its ability to 
nonselective intercalate into the backbone of several classes of amyloids (94, 95).  Since 
my paradigm consists of an in vitro platform for the conversion of PrPC to PrPSc, I 
hypothesize that  effective molecules will influence protein protein interactions through 
(i) binding to the PrPC and preventing its conversion to PrPSc, (ii) binding to PrPSc and 
prevent the recruitment of PrPC, (iii) targeting the particular  glycosylation preferences of 
each prion strain, or (iv) binding to still unknown co-factors present in the brain 
homogenate that could alter the conversion of each specific prion strain.  
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Only three of the anti-prion molecules were effective against one or more mouse 
prion strains (Figure 10). Specifically, all three strains were inhibited by 10 µM tannic 
acid; however, strain specific inhibition was seen for Congo red and thioflavin T. Although 
RML and ME7 are both derived from scrapie (47), they did it from different sources of 
this infectious agent. Consequently, both mouse-adapted prion strains display different 
glycosylation profiles and generate different lesion patterns in brains of experimental 
subjects. This information strongly supports the notion of both being different 
“conformational” strains, and that may be a leading reason as to why Congo red and 
thioflavin T inhibited RML but not ME7. Congo Red did not show selective strain inhibition 
for the hamster prion strains tested in this study, even at the highest concentration tested 
(100 µM). In the same line, I observed that curcumin selectively inhibited the replication 
of HY and 263K prions, but not SSLOW (Figure 11).  
Tannic acid is considered to be a polyphenol inhibitor of amyloid aggregation and 
found naturally in tea, red wine, and nuts. Based on previous studies performed to 
studied its inhibition against prions (49), its mechanism is believed to be through direct 
interactions with PrP. Considering inhibition was observed in all six strains but required 
a high concentration for inhibition of HY when dissolved in DMSO, I predict that tannic 
acid’s mechanism may be altered due to the specific biochemical characteristics of HY. 
Congo red and Thioflavin T are both used as dyes in histological studies in order to 
visualize amyloid deposits (96). These dyes are believed to interact with the b-pleated 
sheet found in the secondary structure of amyloid aggregates (97). The usage of these 
dyes as inhibitors would suggest that through inserts into the deposits, they prevent the 
recruitment of PrPC by PrPSc. The lack of inhibition seen with ME7 for both of these 
compounds would indicate that the unique conformation associated with this strain 
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protects its b-pleated sheet and does not allow for the molecules to bind.  As for the other 
five strains, these dyes may not only be interrupting the conversion process by (1) 
blocking the interaction between PrPC and PrPSc but also (2) obstructing the ability for 
PrPSc to misfold properly thus further disrupting the assembly of the aggregate.  
Quinacrine is considered to be an anti-malaria treatment (98). Concerning 
quinacrine as a treatment option against prions, studies have been conducted in cell 
models, animal models and in human clinical trials. In cell model studies tested against 
scrapie, it was reported that quinacrine reduces the growth of abnormal prion protein 
deposits (49); however, when tested against chronic wasting disease, it aided in the 
accumulation of PrPSc (99). When administered in mice models against a mouse adapted 
BSE strain, a decrease in PrPSc was described (100) and had no effect in humans with 
sporadic CJD patients (101). Since numerous of studies indicted the decrease in PrPSc 
levels, I believe that the mechanism of quinacrine would be at the protein-protein level 
which makes my technique of 96wp-PMCA a viable platform to test this theory.  
Considering no inhibition was observed against any of the strains, possible explanations 
for this could be (1) quinacrine does not inhibit by binding to either forms of the prion 
protein, (2) the usage of sonication breaks any interaction that may be form between 
quinacrine and the prion protein, or (3) similar to chronic wasting disease, quinacrine 
helps in the creation of PrPSc of the strains tested.  
Similarities can be seen between prion diseases and other neurogenerative 
diseases, such as Alzheimer’s and Parkinson’s disease. These diseases are associated 
with the misfolding of proteins and histological dyes such as thioflavin to bind to misfolded 
protein aggregates despite the protein composition of these aggregates (95). Based on 
this knowledge, I postulated that anti-amyloid molecules may be effective in inhibiting 
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prions as well. The anti-amyloid molecules (Figures 13 & 14) tested in this project have 
been shown to inhibit the aggregation of protein linked to Alzheimer’s and Parkinson’s 
disease. Azure A, azure B, azure C, and thionin acetate all belong to a class of drugs 
called phenothiazines (76) and have all been shown to inhibit Aβ aggregation and tau 
filament formation. Rhodanine inhibits the aggregation of tau (102) and quinacrine 
mustard is considered to be a structural relative of quinacrine which in turn may have a 
different inhibitory effect. When comparing the anti-amyloid molecules’ effectiveness 
against the mouse prion strains (Figure 13) in comparison to the anti-prion molecules, I 
was able to see that two of the molecules inhibited prion replication at a concentration 
as low as 1 µM. This contrasts with the lowest concentration found for the anti-prion 
molecules, from which the most effectives worked at a minimum concentration of 10 µM. 
The difference in the chemical structure of azure C in comparison to azure A and azure 
B can be the reasoning behind the lower concentration of inhibition seen when tested 
against HY.  
Inhibition was seen with all four phenothiazines. When azure A and azure B were 
used in mouse models against AD, it was shown to stimulate protein degradation (103). 
Assuming these molecules are not selective towards amyloid-b and various inhibition 
concentrations seen between these two molecules along with azure C for the six strains, 
the inhibitions seen can be attributed to the success of each molecule to promote PrP 
degradation. Due to the utilization of PMCA to evaluate these molecules, I am unable to 
determine which form of the prion protein is targeted. Azure A, azure B, and thionin 
acetate are used as a dye and their mechanism of binding is through intercalation (104). 
Since thioflavin T follows a similar mode of action, I believe that these three molecules 
could be behaving very similar to thioflavin T. Comparing the structures of these 
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compounds to thioflavin T, they all have three cyclic structures. Further studies would be 
required; however, these structures could aid in their intercalation into the misfolded 
protein.  
It is important to note that quinacrine is typically accepted as a good anti-prion 
drug compared to its structural relatives (75, 100); however, for the hamster strains, I am 
able to see a better performance for quinacrine mustard instead of the parental structure. 
The difference in inhibition could be as a result of the presence of the two chloride 
functional groups attached to the quinacrine mustard dihydrochloride. Because inhibition 
with quinacrine mustard was only seen with hamster prion strains binding to cofactors 
necessary for prion misfolding which are present in the hamster brain extract but not in 
the mouse counterpart may assist in the species-specific inhibitory effect of this 
molecule. Further in silico studies may assist in clarifying the relationship between small 
molecule composition and their interaction with prions in a strain-specific manner.  
It is important to mention that due to the great sensitivity and strength of the PMCA 
technology (93), it is not surprising that some molecules worked at lower concentrations 
compared to the ones described using other systems. In that sense, the novel anti-prion 
activity of some molecules from the “anti-amyloid” group look promising for future studies. 
Unfortunately, due to the constraint of the technique utilized, the molecules were only 
tested for their ability to inhibit protein-protein interactions. This could also explain the 
lack of inhibition seen for some of the previously described anti-prion molecules working 
at nanomolar concentrations in cell-based systems (49). Despite six of all the molecules 
showing no inhibition at the concentration tested, strain-specific inhibition can be seen 
for five of the molecules in hamster prions and four of the molecules in mouse prion 
strains. When comparing the molecules between both mice and hamsters, further strain 
specific inhibition can be seen. Based on these results, my original hypothesis is 
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supported and confirm the need for strain-specific treatment options. I believe that the 
current PMCA format can easily be applied towards testing a library of compounds 
showing to inhibit other amyloids, as well as larger libraries. The optimization of PMCA 
for high throughput screening will provide for another route to find treatment options for 
prions along with being utilized in the diagnostic process of prion disease. Another benefit 
and application of the HT-PMCA technique is the ability to apply it towards the study of 
proteins involved in other neurodegenerative diseases, such as, Alzheimer’s and 
Parkinson’s.  
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